跳至主要内容
临床试验/NCT00607178
NCT00607178已完成2 期

Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris

Shahid Beheshti University of Medical Sciences2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2008年1月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
300
试验地点
2
主要终点
Cardiovascular death

研究概览

简要总结

Influenza vaccine reduces the cardiovascular events in post-myocardial infarction (MI) patients and in those with stable angina (SA).

详细描述

A connection between infectious processes and atherosclerosis is repeatedly reported [1]. Acute respiratory infection was found to be associated with myocardial infarction (MI) [2,3] and a number of epidemiological studies found that mortality attributable to cardiovascular diseases is increased during influenza epidemics [4]. Naghavi et al [5] in a case-control study of patients with coronary artery disease (CAD) found that vaccination against influenza was negatively associated with the development of new MI during the same influenza season. While some clinical trials found influenza vaccine effective in secondary prevention of cardiovascular adverse events [6,7], a large trial [8] failed to approve such an efficacy. Furthermore, a recent review of published trials on the subject concluded that frailty selection bias and use of non-specific endpoints such as all cause mortality have led cohort studies to greatly exaggerate vaccine benefits and that the remaining evidence base is currently insufficient to indicate the magnitude of the mortality benefit of the vaccination program [9].

This study aims to assess the efficacy of vaccine in secondary prevention of cardiovascular events in MI and stable angina (SA) patients using specific endpoints including reliable quantitative tools.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
25 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute phase) as defined by:
  • Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:
  • Ischemic symptoms
  • Development of pathologic Qwaves on the ECG
  • ECG changes indicative of ischemia (ST segment elevation or depression); OR
  • Coronary artery intervention (e.g., coronary angioplasty).
  • Pathologic findings of an acute MI [12]
  • Patients with stable angina pectoris and documented coronary artery stenosis (angiography).

排除标准

  • Any acute disease
  • Chronic liver or kidney diseases
  • Conditions accompanied by immunosuppression (like organ transplantation, HIV)
  • Diagnosed malignancy
  • Incubation with influenza vaccine within the past 5 years
  • Any psychological disease that interferes with regular follow-up
  • Congestive heart failure (Killip class IV)
  • Unstable angina, and contradictions of vaccine incubation (like egg allergy).

结局指标

主要结局

Cardiovascular death

时间窗: 6 months

次要结局

  • Acute coronary syndrome (MI or unstable angina)(6 months)
  • Admission for Coronary Artery Disease(6 months)
  • Angina severity (Seattle Angina Questionnaire [10])(6 months)
  • Coronary artery stenosis (modified Gensini score [11])(6 months)
  • Coronary revascularization (artery bypass graft or percutaneous coronary intervention)(6 months)
  • Influenza infection(6 months)

研究者

研究点 (2)

Loading locations...

相似试验

The Efficacy of Influenza Vaccine in Reducing... | 临床试验